Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment

Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment

PURPOSE The current study aims to investigate the neurodevelopment of premature infants after intravitreal injections of bevacizumab (IVB) for the treatment of retinopathy of prematurity (ROP) up to the age of 2 years. METHODS The study design was retrospective observational case series conducted at an institutional referral center. Infants with type 1 ROP were classified into 3 groups: laser...

Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity.

BACKGROUND AND OBJECTIVE Bevacizumab intravitreal injection, a vascular endothelial growth factor inhibitor, is used to treat retinopathy of prematurity (ROP). However, concerns have been raised regarding its systemic absorption and effect on developing tissues including brain. This study compared neurodevelopment at 18 months' corrected age in preterm infants of <29 weeks' gestation treated wi...

Significant Treatment Failure With Intravitreous Bevacizumab for Retinopathy of Prematurity

zumab therapy as compared with children undergoing retinal laser coagulation were significantly less myopic at 1 year of follow-up. Although the cause for myopization in children treated for ROP has remained unclear so far, the results of our study are in line with previous investigations in which myopization was more pronounced in children randomized for the more invasive cryotherapy than in t...

Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity.

zumab therapy as compared with children undergoing retinal laser coagulation were significantly less myopic at 1 year of follow-up. Although the cause for myopization in children treated for ROP has remained unclear so far, the results of our study are in line with previous investigations in which myopization was more pronounced in children randomized for the more invasive cryotherapy than in t...

Bevacizumab for retinopathy of prematurity.